DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Niraparib
Niraparib
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide
AHFS Pharmacologic-Therapeutic Classification System
Cancer Drug Pharmacology Table
New Drug Update: the Next Step in Personalized Medicine
Olaparib and Temozolomide in SCLC
Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant
Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
OUH Formulary Approved for Use in Breast Surgery
Olaparib in Combination with Irinotecan, Cisplatin, and Mitomycin C in Patients with Advanced Pancreatic Cancer
New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
Evaluation of an Individualized Starting Dose of Niraparib in The
Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy Gwynn Ison, Lynn J
Niraparib) Capsules, for Oral Use Monthly for the First Year and Periodically Thereafter During Treatment Initial U.S
| Oral Chemotherapy Monitoring & Counseling
Lists of Medicinal Products for Rare Diseases in Europe*
Table S1. Clinical Trials Implicating Galectins As Biomarkers (1)
5.01.540 Miscellaneous Oncology Drugs
PARP Inhibitors As Therapeutics: Beyond Modulation of Parylation
Top View
Posttranscriptional Regulation of PARG Mrna by Hur Facilitates DNA Repair and Resistance to PARP Inhibitors Saswati N
Targeting NAD Biosynthesis Overcomes Panobinostat And
Advanced Pediatric Diffuse Pontine Glioma Murine Models Pave the Way Towards Precision Medicine
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation
Minutes of the CHMP Meeting 25-29 January 2021
Gynaecological Cancers
Separately Chargeable Drugs List
(PARP) Inhibitors in Ovarian Cancer: Quo Vadis?
Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
FEP 5 Tier Rx Drug Formulary (607) Standard Option
PARP Inhibitors As Potential Therapeutic Agents for Various Cancers
Development of a 3D Functional Assay and Identification of Biomarkers
Marketed and Late Stage Pipeline
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
PARP Inhibitors: Their Role Across Tumor Types
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
SELECTED PHARMACEUTICALS in LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION As of 1/22/20 Therapeutic Area Product Name Indication Sought U.S
Adult Antiemetic Management of Chemotherapy-Induced Nausea
State and Specialty Pharmacy Drug Reimbursement Rates
Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments
Photodynamic Therapy and Hyperthermia in Combination Treatment—Neglected Forces in the Fight Against Cancer
Emetogenic Potential of Antineoplastic Agents
An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
NG161 NHS England Interim Treatment Options During the COVID 19 Pandemic
ZEJULA (Niraparib) Capsules, for Oral Use DOSAGE FORMS and STRENGTHS Initial U.S
Proton Pump Inhibitors and Oncologic Treatment Efficacy
Oncology Proposal
Comprehensive Analysis of Chemotherapeutic Agents That Induce Infectious Neutropenia
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant
Wise Management of Ovarian Cancer: on the Cutting Edge
New Century Health Policy Changes May 2021
211651Orig1s000
Zejula 100 Mg Hard Capsules
David Palchak MD Erick Hjortsvang MD Phone: 805.474.9143 Fax: 805.474.9569
[email protected]
10-9-16
News & Analysis
PD-1/PD-L1 Blockade Combination Approaches in Metastatic Breast Cancer
Study Protocol 3000-PN162-01-001 Amendment 2
PARP Inhibitors in Pancreatic Cancer: Molecular Mechanisms and Clinical
CY 2017 CDER Drug and Biologic Calendar Year Priority Approvals As of December 31, 2017
DNA Damage Repair As a Target in Pancreatic Cancer: State-Of- The-Art and Future Perspectives Gut: First Published As 10.1136/Gutjnl-2019-319984 on 27 August 2020
CVS Caremark® Value Formulary Effective As of 07/01/2021
Drugs Formulary
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Policy Drug(S) Type of Change Brief Description of Policy Change UM ONC 1035 5HT3 Receptor Formatting N/A
Standard Oncology Criteria Policy Number: Pending
Takeda Quarterly Financial Report
Summary of Utilization Management (UM) Program Changes April (2Nd Posting) 2020
Analysis of PARP Inhibitor Toxicity by Multidimensional fluorescence Microscopy Reveals Mechanisms of Sensitivity and Resistance
Do Not Tube List
Development of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of BRCA-Mutated Breast Cancer
Combination of a Hypomethylating Agent and Inhibitors of PARP And
FDA Approvals for the First 6 Months of 2016 Include Clovis’S Rucaparib, Which the Company the FDA Approved 13 New Drugs in the First 6 Months of This Year (TABLE 1)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer Jason
208558Orig1s000
Hazardous Medication Precautions: Personal Protective Equipment (Ppe)
Minutes PRAC Meeting on 14 -17 April 2020
November 2020
Current State and Future Perspectives in Breast Cancer